Literature DB >> 21549792

Immune responses to an attenuated West Nile virus NS4B-P38G mutant strain.

Thomas Welte1, Guorui Xie, Jason A Wicker, Melissa C Whiteman, Li Li, Aparna Rachamallu, Alan Barrett, Tian Wang.   

Abstract

The nonstructural (NS) proteins of West Nile virus (WNV) have been associated with participation in evasion of host innate immune defenses. In the present study, we characterized immune response to an attenuated WNV strain, which has a P38G substitution in the NS4B protein. The WNV NS4B-P38G mutant induced a lower level of viremia and no lethality in C57BL/6 (B6) mice following a systemic infection. Interestingly, there were higher type 1 IFNs and IL-1β responses compared to mice infected by wild-type WNV. NS4B-P38G mutant-infected mice also showed stronger effector and memory T cell responses. WNV specific antibody responses were not different between mice infected with these two viruses. As a consequence, all mice were protected from a secondary infection with a lethal dose of wild-type WNV following a primary infection with NS4B-P38G mutant. Moreover, NS4B-P38G mutant infection in cultured bone-marrow derived dendritic cells (DCs) were shown to have a reduced replication rate, but a higher level of innate cytokine production than wild-type WNV, some of which were dependent on Myd88 signaling. In conclusion, the NS4B-P38G mutant strain induces higher protective innate and adaptive immune response in mice, which results in a lower viremia and no lethality in either primary or secondary infection, suggesting a high potential as an attenuating mutation in a vaccine candidate.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21549792      PMCID: PMC3114109          DOI: 10.1016/j.vaccine.2011.04.057

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  45 in total

1.  Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses.

Authors:  Jorge L Muñoz-Jordán; Maudry Laurent-Rolle; Joseph Ashour; Luis Martínez-Sobrido; Mundrigi Ashok; W Ian Lipkin; Adolfo García-Sastre
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection.

Authors:  James D Brien; Jennifer L Uhrlaub; Janko Nikolich-Zugich
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

3.  The innate immune adaptor molecule MyD88 restricts West Nile virus replication and spread in neurons of the central nervous system.

Authors:  Kristy J Szretter; Stephane Daffis; Jigisha Patel; Mehul S Suthar; Robyn S Klein; Michael Gale; Michael S Diamond
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

4.  Characterization of West Nile virus live vaccine candidates attenuated by capsid deletion mutations.

Authors:  Petra Schlick; Regina M Kofler; Beate Schittl; Christian Taucher; Eszter Nagy; Andreas Meinke; Christian W Mandl
Journal:  Vaccine       Date:  2010-06-25       Impact factor: 3.641

5.  Isolation of West Nile virus from mosquitoes, crows, and a Cooper's hawk in Connecticut.

Authors:  J F Anderson; T G Andreadis; C R Vossbrinck; S Tirrell; E M Wakem; R A French; A E Garmendia; H J Van Kruiningen
Journal:  Science       Date:  1999-12-17       Impact factor: 47.728

6.  Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States.

Authors:  R S Lanciotti; J T Roehrig; V Deubel; J Smith; M Parker; K Steele; B Crise; K E Volpe; M B Crabtree; J H Scherret; R A Hall; J S MacKenzie; C B Cropp; B Panigrahy; E Ostlund; B Schmitt; M Malkinson; C Banet; J Weissman; N Komar; H M Savage; W Stone; T McNamara; D J Gubler
Journal:  Science       Date:  1999-12-17       Impact factor: 47.728

7.  Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing.

Authors:  Terrence Town; Fengwei Bai; Tian Wang; Amber T Kaplan; Feng Qian; Ruth R Montgomery; John F Anderson; Richard A Flavell; Erol Fikrig
Journal:  Immunity       Date:  2009-02-05       Impact factor: 31.745

8.  MyD88 and interferon-alpha/beta are differentially required for dendritic cell maturation but dispensable for development of protective memory against Listeria.

Authors:  Miguel A Tam; Mary Jo Wick
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

Review 9.  Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.

Authors:  Bruno Guy; Farshad Guirakhoo; Veronique Barban; Stephen Higgs; Thomas P Monath; Jean Lang
Journal:  Vaccine       Date:  2009-10-04       Impact factor: 3.641

10.  The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling.

Authors:  Maudry Laurent-Rolle; Elena F Boer; Kirk J Lubick; James B Wolfinbarger; Aaron B Carmody; Barry Rockx; Wenjun Liu; Joseph Ashour; W Lesley Shupert; Michael R Holbrook; Alan D Barrett; Peter W Mason; Marshall E Bloom; Adolfo García-Sastre; Alexander A Khromykh; Sonja M Best
Journal:  J Virol       Date:  2010-01-27       Impact factor: 5.103

View more
  19 in total

Review 1.  West Nile virus: A re-emerging pathogen revisited.

Authors:  Miguel A Martín-Acebes; Juan-Carlos Saiz
Journal:  World J Virol       Date:  2012-04-12

2.  Reconciling West Nile virus with the autophagic pathway.

Authors:  Miguel A Martín-Acebes; Ana-Belén Blázquez; Juan-Carlos Saiz
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

3.  A West Nile virus NS4B-P38G mutant strain induces cell intrinsic innate cytokine responses in human monocytic and macrophage cells.

Authors:  Guorui Xie; Huanle Luo; Bing Tian; Brian Mann; Xiaoyong Bao; Jere McBride; Robert Tesh; Alan D Barrett; Tian Wang
Journal:  Vaccine       Date:  2015-01-03       Impact factor: 3.641

Review 4.  Virulence determinants of West Nile virus: how can these be used for vaccine design?

Authors:  Jaclyn A Kaiser; Tian Wang; Alan Dt Barrett
Journal:  Future Virol       Date:  2017-04-28       Impact factor: 1.831

5.  Replication-Defective West Nile Virus with NS1 Deletion as a New Vaccine Platform for Flavivirus.

Authors:  Na Li; Ya-Nan Zhang; Cheng-Lin Deng; Pei-Yong Shi; Zhi-Ming Yuan; Bo Zhang
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

6.  In vitro analysis of MyD88-mediated cellular immune response to West Nile virus mutant strain infection.

Authors:  Guorui Xie; Melissa C Whiteman; Jason A Wicker; Alan D T Barrett; Tian Wang
Journal:  J Vis Exp       Date:  2014-11-27       Impact factor: 1.355

7.  An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody.

Authors:  Nikolai Petrovsky; Maximilian Larena; Venkatraman Siddharthan; Natalie A Prow; Roy A Hall; Mario Lobigs; John Morrey
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

8.  Vertebrate attenuated West Nile virus mutants have differing effects on vector competence in Culex tarsalis mosquitoes.

Authors:  Greta A Van Slyke; Yongqing Jia; Melissa C Whiteman; Jason A Wicker; Alan D T Barrett; Laura D Kramer
Journal:  J Gen Virol       Date:  2013-01-09       Impact factor: 3.891

9.  A West Nile virus NS4B-P38G mutant strain induces adaptive immunity via TLR7-MyD88-dependent and independent signaling pathways.

Authors:  Guorui Xie; Thomas Welte; Jia Wang; Melissa C Whiteman; Jason A Wicker; Vandana Saxena; Yingzi Cong; Alan D T Barrett; Tian Wang
Journal:  Vaccine       Date:  2013-07-08       Impact factor: 3.641

10.  Dysregulation of Toll-Like Receptor 7 Compromises Innate and Adaptive T Cell Responses and Host Resistance to an Attenuated West Nile Virus Infection in Old Mice.

Authors:  Guorui Xie; Huanle Luo; Lan Pang; Bi-Hung Peng; Evandro Winkelmann; Brenna McGruder; Joseph Hesse; Melissa Whiteman; Gerald Campbell; Gregg N Milligan; Yingzi Cong; Alan D Barrett; Tian Wang
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.